Receive news by e-mail

#
 

Enter your e-mail in the field below to receive directly the news that appears on this page.

 

topics : related - all Explore

Shopping Categories

  1. 1. Cell Phones
  2. 2. Smartphones
  3. 3. Digital Cameras
  4. 4. Laptop Computers
  5. 5. Processors
  6. 6. Motherboards
  7. 7. LCD Monitors
  8. 8. Graphics Cards
  9. 9. GPS
  10. 10. Digital Camcorders
  11. 11. Printers
  12. 12. Desktop Computers
  13. 13. Sedans
  14. 14. Coupes & Convertibles
  15. 15. 4x4

Wikio Shopping

  1. 1. Automotive
  2. 2. Beauty & Fragrances
  3. 3. Books
  4. 4. Car/Motorbike
  5. 5. CD
  6. 6. Clothing, Accessories & Shoes
  7. 7. Communication
  8. 8. Computers
  9. 9. DVD
  10. 10. Electronics
  11. 11. Flowers & Gifts
  12. 12. Gourmet & Foods
  13. 13. Health & Personal Care
  14. 14. Home & Garden
  15. 15. Hotels
  16. 16. Household Appliances
  17. 17. Jewelry & Watches
  18. 18. Musical Instruments
  19. 19. Sports & Outdoors
  20. 20. Toys & Baby
  21. 21. Video Games

Participate



Genzyme



Sort by : relevance - date - popularity
4Vote!

Marsha Fanucci Joins Ironwood Board of Directors

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Marsha Fanucci has joined its Board of Directors. Ms. Fanucci served at Millennium Pharmaceuticals, Inc. from 2000-2009 in a number of senior positions, including chief financial officer and senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development...

5Vote!

Zacks Sell List Highlights: Pinnacle Financial Partners, Marten Transport Ltd., Genzyme Corporation and MDS Inc.

CHICAGO--(BUSINESS WIRE)--Zacks.com releases details on a group of stocks that are currently members of the exclusive Zacks #5 Rank List – Stocks to Sell Now. These stocks are currently rated as a Zacks Rank #5 (Strong Sell): Pinnacle Financial Partners (Nasdaq: PNFP) and Marten Transport Ltd. (Nasdaq: MRTN). Further, Zacks announced #4 Rankings (Sell) on two other widely held stocks: Genzyme...

4Vote!

First Patient Enrolled In Phase 3 Trials Of Genzyme Oral Capsule For Gaucher Disease

Genzyme Corporation (NASDAQ: GENZ) announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

7Vote!

Genzyme Corporation Q3 2009 Earnings Call Transcript

Genzyme Corporation ( GENZ ) Q3 2009 Earnings Call Transcript October 21, 2009 11:00 am ET Complete Story »

4Vote!

First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule. The first trial, known as...

5Vote!

NASDAQ 100 components and analyst ratings

In reply to Cara's Commentary & Community Chat, Thursday, Oct. 15, 2009 : Rating Company Name Symbol 1.0 Ryanair Holdings plc RYAAY 1.4 Stericycle, Inc. SRCL 1.5 Activision Blizzard, Inc ATVI 1.6 Teva Pharmaceutical Industries Limited TEVA 1.6 Warner Chilcott plc WCRX 1.7 Cognizant Technology Solutions Corp CTSH 1.7 Express Scripts, Inc. ESRX 1.7 Gilead Sciences, Inc. GILD 1.8 Foster Wheeler AG....

5Vote!

Scientists Name Genzyme a Top Employer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology...

4Vote!

Genzyme Receives FDA Complete Response Letter For Clolar

Genzyme Corporation (Nasdaq: GENZ) announced that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.

4Vote!

Genzyme Receives FDA Complete Response Letter for Clolar

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA provided a complete response letter regarding the company's supplemental New Drug Application for Clolar® (clofarabine) in previously untreated older adult patients with acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor. The agency recommended a randomized, controlled...

4Vote!

Genzyme Named to Dow Jones Sustainability World and North American Indexes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it was included on both the 2009 Dow Jones Sustainability World Index and North American Index. This marks the fifth consecutive year Genzyme has been named to the Dow Jones Sustainability North American Index and the first year the company has been named to the Dow Jones Sustainability World Index. Genzyme is...

7Vote!

Industrial Info Resources: Genzyme Survives Virus Infection at Allston Manufacturing Plant and Resumes Drug Production, an Industrial Info News Alert

SUGAR LAND, TX (MARKET WIRE) Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- A virus infection forced the Genzyme Corporation (NASDAQ: GENZ) to shut down the company's biopharmaceutical plant in Allston Landing, Massachusetts. The virus strain Vesivirus 2117, which was found in the site's six bioreactors, interferes with the growth of CHO cells, a component in biologic...

4Vote!

Genzyme's Campath Meets Primary Endpoint In Phase 3 Combination Therapy Trial For Chronic Lymphocytic Leukemia

Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant improvement in progression free survival (PFS).

5Vote!

Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that its randomized Phase 3 clinical trial investigating Campath® (alemtuzumab) in combination with Fludara® (fludarabine phosphate) in relapsed or refractory chronic lymphocytic leukemia (CLL) patients met its primary endpoint by demonstrating a significant improvement in progression free survival (PFS)....

5Vote!

Genzyme Provides Update on Cerezyme and Fabrazyme Supply

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (NASDAQ: GENZ) today provided an update on its progress to restore supplies of Cerezyme® (imiglucerase for injection) and Fabrazyme® (agalsidase beta) for patients worldwide and revised its 2009 revenue guidance for these products. The company is now approximately half-way through the anticipated shortage period for Cerezyme and Fabrazyme,...

5Vote!

Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis (MS) trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. The CAMMS223 Phase 2...